{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:47:02Z","timestamp":1786999622112,"version":"build-2736575974"},"reference-count":40,"publisher":"Cambridge University Press (CUP)","issue":"4","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S1092852919001500_sec1\" sec-type=\"other\">\n                    <jats:title>Background and objective.<\/jats:title>\n                    <jats:p>Glutamate dysfunction has been shown to be associated with pathophysiology of obsessive\u2013compulsive disorder (OCD). Our objective is to survey the effects of pregabalin (a glutamate-modulating agent) as an augmenting treatment for resistant OCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1092852919001500_sec2\" sec-type=\"other\">\n                    <jats:title>Patients and methods.<\/jats:title>\n                    <jats:p>In this 12-week double-blind placebo-controlled clinical trial, 56 patients with resistant OCD were randomly allocated to receive either pregabalin or placebo plus their current medication (sertraline). Yale\u2013Brown Obsessive Compulsive Scale (Y-BOCS) was used to evaluate the outcomes. Adverse effects were also registered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1092852919001500_sec3\" sec-type=\"results\">\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Of the 56 patients with resistant OCD who were randomly allocated in 2 groups of pregabalin (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a028) and placebo group (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a028), 42 patients (22 in pregabalin group and 20 in placebo group) completed the trial. Throughout the trial, the mean score decreased from 26.13\u00b1 7.03 to 8.81\u00a0\u00b1\u00a03.47 in the pregabalin group (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00) and from 26.85\u00a0\u00b1\u00a04.34 to 17.63\u00a0\u00b1\u00a04.22 in the placebo group (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00). At the end of trial, 16 (57.14%) patients in the pregabalin group and 2 (7.14%) patients in the placebo group showed more than 35% decline in YBOCS (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a0.01). The pregabalin group showed good tolerability and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1092852919001500_sec4\" sec-type=\"conclusions\">\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Our study revealed that pregabalin, as an augmenting medication, is more effective than placebo in the treatment of patients with resistant OCD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/s1092852919001500","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T03:02:04Z","timestamp":1571972524000},"page":"552-556","source":"Crossref","is-referenced-by-count":24,"title":["Pregabalin augmentation for resistant obsessive\u2013compulsive disorder: a double-blind placebo-controlled clinical trial"],"prefix":"10.1017","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2283-2751","authenticated-orcid":false,"given":"Arash","family":"Mowla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnoosh","family":"Ghaedsharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"S1092852919001500_ref31","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.pbb.2011.10.007","article-title":"The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder","volume":"100","author":"Wu","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"key":"S1092852919001500_ref2","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2008.94"},{"key":"S1092852919001500_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2004.08.004"},{"key":"S1092852919001500_ref18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/PRBM.S58601","article-title":"A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders","volume":"8","author":"Grados","year":"2015","journal-title":"Psychol Res Behav Manag"},{"key":"S1092852919001500_ref20","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852912000065"},{"key":"S1092852919001500_ref39","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900017119"},{"key":"S1092852919001500_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2014.05.006"},{"key":"S1092852919001500_ref8","doi-asserted-by":"publisher","DOI":"10.2174\/0929867325666171222163645"},{"key":"S1092852919001500_ref34","doi-asserted-by":"publisher","DOI":"10.1097\/01.yic.0000199453.54799.cc"},{"key":"S1092852919001500_ref9","doi-asserted-by":"publisher","DOI":"10.1177\/2045125314560739"},{"key":"S1092852919001500_ref29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0165-0173(94)00007-C","article-title":"Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamocortical loop","volume":"20","author":"Parent","year":"1995","journal-title":"Brain Res Brain Res Rev"},{"key":"S1092852919001500_ref35","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181c8b44f"},{"key":"S1092852919001500_ref6","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.114.150136"},{"key":"S1092852919001500_ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.05.015"},{"key":"S1092852919001500_ref1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.593"},{"key":"S1092852919001500_ref4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-clinpsy-032210-104533"},{"key":"S1092852919001500_ref10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S1461145703003730","article-title":"Risperidone augmentation in treatment-resistant\u00a0obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"6","author":"Hollander","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"S1092852919001500_ref11","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0709"},{"key":"S1092852919001500_ref12","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2005.41.8.910482"},{"key":"S1092852919001500_ref13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1517\/13543784.2012.703179","article-title":"Pregabalin in clinical psychiatry and addiction: pros and cons","volume":"21","author":"Martinotti","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"S1092852919001500_ref14","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1517\/13543784.2012.685651","article-title":"Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence","volume":"21","author":"Oulis","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"S1092852919001500_ref15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3940(00)00769-2","article-title":"Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin","volume":"280","author":"Dooley","year":"2000","journal-title":"Neurosci Lett"},{"key":"S1092852919001500_ref19","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.343"},{"key":"S1092852919001500_ref17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300733"},{"key":"S1092852919001500_ref21","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000651"},{"key":"S1092852919001500_ref37","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jpsychires.2008.10.007","article-title":"Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults","volume":"43","author":"Greenberg","year":"2009","journal-title":"J Psychiatr Res"},{"key":"S1092852919001500_ref22","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/npp.2009.77","article-title":"Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder","volume":"34","author":"Bhattacharyya","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"S1092852919001500_ref23","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283466657"},{"key":"S1092852919001500_ref24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00406-007-0798-z","article-title":"Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?","volume":"258","author":"Onder","year":"2008","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"S1092852919001500_ref25","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000393848.35132.ff"},{"key":"S1092852919001500_ref26","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810110048007"},{"key":"S1092852919001500_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2018.03.014"},{"key":"S1092852919001500_ref30","doi-asserted-by":"publisher","DOI":"10.2174\/1875397300802010062"},{"key":"S1092852919001500_ref32","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181c856de"},{"key":"S1092852919001500_ref33","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111431751"},{"key":"S1092852919001500_ref36","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10l06653"},{"key":"S1092852919001500_ref38","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07050776"},{"key":"S1092852919001500_ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0004867418806370"},{"key":"S1092852919001500_ref7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pnpbp.2018.12.009","article-title":"Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: a network meta-analysis","volume":"90","author":"Zhou","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"S1092852919001500_ref40","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0717"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852919001500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T05:31:59Z","timestamp":1597728719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852919001500\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1092852919001500"],"URL":"https:\/\/doi.org\/10.1017\/s1092852919001500","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]}}}